WALNUT, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Armlogi Holding Corp. (“Armlogi” or the “Company”) (Nasdaq: BTOC), a U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions related to warehouse management and order fulfillment, today announced financial results for its first quarter ended September 30, 2025 of fiscal year 2026. First Quarter Fiscal Year 2026 Financial Highlights:Total revenue increased by 16.5% to $49.5 million for the first quarter of fiscal year 2026, compared to $42.5 million for the first quarter of fiscal year 2025, driven by continued strong demand for both transportation and warehousing services. Transportation services revenue grew 12.6% to $32.1 million, reflecting increased shipment volumes from new warehouse locations. Warehousing services...

HOUSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) — Battalion Oil Corporation (NYSE American: BATL, “Battalion” or the “Company”) today announced financial and operating results for the third quarter of 2025. Key HighlightsGenerated third quarter 2025 sales volumes of 12,293 barrels of oil equivalent per day (“Boe/d”) (53% oil) AGI facility remains out of service Gas Production is being treated by third party The Company has entered into an amendment of its existing credit facility allowing additional operational flexibility The Company continues to pursue potential merger, acquisition and divestiture opportunitiesManagement Comments Drilling and completion operations concluded in the West Quito Draw with two wells coming online and producing an average of 883 Boe/ day over the first 120 days of production. Well operations yielded more...

KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) — Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; “BGMS” or the “Company” (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced third quarter financial results and provided a business update. Highlights of the third quarter ended September 30, 2025, or in some cases shortly thereafter, include:In July, the Company implemented a one-for-fifteen reverse stock split effective on July 7, 2025 on which day the Company’s common stock began trading on a split-adjusted basis in an effort to meet the share bid price requirements of The Nasdaq Capital Market. In September, the Company entered into a Warrant Exchange Agreement (the...

Strengthened financial position and de-risked path forward to build North America’s first cobalt sulfate refinery TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) announces the filing of its financial results for the third quarter ended September 30, 2025, including key activities supporting the Company’s focus on delivering its cobalt sulfate refinery in Temiskaming Shores, Ontario. Progress during the quarter reflects Electra’s renewed momentum in establishing a North American battery materials supply chain. Alongside the Company’s significant financial accomplishments, recent strategic activities include feedstock testing from Ontario and Idaho, underpinning the long-term importance of domestic mineral assets and reinforcing Electra’s role...

~ Pivotal Financial Turnaround Completed, Fortifying the Foundation for Renewed Operational Momentum ~ ~ Strongest Balance Sheet in Several Years, Powered by $20 Million Private Placement and Zero Debt ~ ~ Continued Revenue Diversification and Lean Cost Structure Driving Clear Path to Profitability and Growth ~SANTA MONICA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Super League (Nasdaq: SLE) (the “Company”), a leader in playable media trusted by global brands to reach and activate gaming audiences through playable ads and gamified content, today released third quarter 2025 financial results. Super League Chief Executive Officer, Matt Edelman Commented: “Our third quarter and the initial weeks of October represented a pivotal moment for Super League, a new beginning punctuated by decisive financial, operational, and strategic...

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of Photonic Integrated Circuits (PICs), light sources and optical modules for the AI and data center markets, today reported its unaudited condensed consolidated financial results for the third quarter ended September 30, 2025. The Company’s financial results as well as the Management Discussion and Analysis have been filed on SEDAR+. All financial figures are in United States dollars (“USD”) unless otherwise indicated. Management Commentary: “The third quarter of 2025 demonstrated continued progress toward commercialization of our optical engine and light source products. The placement of two successive initial production orders from two key customers valued at over $5.6 million...

Conference Call Scheduled for today, November 13, 2025, at 5:00pm ET GARDNER, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) — Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its first quarter fiscal year 2026 for the period ended September 30, 2025. Q1 2026 Financial Highlights (3 Months Ended September 30, 2025):Revenue was $6.7 million, a quarterly record, compared to $4.2 million in the same quarter of the previous fiscal year, representing growth of approximately 59%. Production revenue was $6.0 million, a quarterly record, compared to $2.6 million in the same quarter of the previous fiscal year, representing growth of approximately 133%. Engineering revenue...

Commercial revenue grew 37%, driven by AI risk assistant adoption United States and Europe accounted for 90% of revenue Balance sheet strengthened by $21 million equity bought deal financing Company reaffirms annual guidance and advances major government programs DENVER, Nov. 13, 2025 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today announced its financial results for the three months ended September 30, 2025. During the quarter, Intermap completed a bought deal public offering and concurrent private placement, raising gross proceeds of $21 million, significantly strengthening its balance sheet, allowing it to invest in commercial markets and positioning the Company to execute large, multiyear contracts. As...

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2025 and provided a summary of recent pipeline and corporate highlights. “Our team is laser focused on driving SENTI-202 clinical development forward. With important milestones achieved in the third quarter, we continue to execute on our dose expansion phase and on enrolling additional patients with relapsed/refractory AML at the Recommended Phase 2 Dose,” commented Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences. “At the upcoming ASH Annual Meeting in December, we will be presenting exciting clinical data from...

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended September 30, 2025, and highlighted recent achievements. “As we continue to advance our pipeline, we are entering an important period for Alumis. Our teams have been working diligently, and we are eagerly anticipating key milestones ahead – with topline Phase 3 ONWARD data for envudeucitinib (envu) in moderate-to-severe plaque psoriasis (PsO) expected to be announced early in the first quarter of 2026, followed by topline Phase 2b LUMUS data in systemic lupus erythematosus (SLE) in the third quarter,” said Martin Babler, President and Chief Executive...